The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
about
c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damageDown-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferationProtein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.Characterization of a novel member of the DOK family that binds and modulates Abl signalingDepletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoformsKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsDOCK5 and DOCK1 regulate Caco-2 intestinal epithelial cell spreading and migration on collagen IVThe SH2 domain-containing proteins in 21 species establish the provenance and scope of phosphotyrosine signaling in eukaryotesModeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug designPhosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in miceSmac mimetics: implications for enhancement of targeted therapies in leukemiaIdentification of a proline-rich sequence in the CD2 cytoplasmic domain critical for regulation of integrin-mediated adhesion and activation of phosphoinositide 3-kinaseExpression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolismTransformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1RHS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcriptionFoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.c-Abl-dependent molecular circuitry involving Smad5 and phosphatidylinositol 3-kinase regulates bone morphogenetic protein-2-induced osteogenesis.An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.Proteomic characterization of HIV-modulated membrane receptors, kinases and signaling proteins involved in novel angiogenic pathways.A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivoMolecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms.Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells.Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemiaBCR/ABL induces multiple abnormalities of cytoskeletal function.Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cellsDifferential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cellsRole of phosphoinositide 3-kinase and the Cbl adaptor protein in coupling the alpha4beta1 integrin to mitogen-activated protein kinase signalling.Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.Crk and CrkL adaptor proteins: networks for physiological and pathological signaling
P2860
Q24295019-63F7F204-37DD-4DEB-9FCC-F6AE53B81F70Q24304940-B90C3F5D-6E25-4F67-8D76-C52D8D9BA57DQ24311296-43962B8A-52D0-4991-A84D-132952F561DFQ24554382-A8EEFC36-D742-4841-8BAA-02934D5B7BA2Q24658292-E80DCDE0-76B6-4D44-B534-543811CF4B87Q26849792-EC444C65-E4BE-4186-B334-06805F442F26Q28116715-C7C12C7B-72E5-47AF-8D3D-9FBB97C55ED0Q28255020-9CDCE1F8-BEE5-4F64-A35E-0798CE502877Q28478748-DFEBC844-27E8-4986-BC49-6193DAF4F34DQ30160146-FB577E7D-8AA7-4C58-9DC6-DB075DB3C7A8Q33510153-B6449E12-64B2-4A15-BDC8-9B26D28F9F89Q33683159-70D813F0-CD76-46D4-B740-882942958C97Q33778252-5DC91E9D-49F4-4690-91F0-01662CB5EB5DQ33967180-F8684422-0984-4CBB-9441-60248238C198Q34186690-7F2FFD3D-95DA-4A97-954E-DEE660C439B3Q34250223-76B52EAC-7AF3-42E7-9109-47F117B355CCQ34260622-E49FB960-6863-4573-949B-4D0BC1F3ED93Q34438500-95A4AAF2-88C7-4146-8820-C27F4EEFF285Q35176353-244CBE8D-2E46-4901-8FF2-9FD2DF5D6BB6Q35212394-3DE08CB2-B6D0-48F0-813E-51B6FE5AA675Q36334327-950C8EE5-D60B-4696-B98C-29A355F9DF01Q36508937-2ADDEE49-2CAB-44BB-ABE2-056CE2C34ACAQ36508969-6C3287B5-2DD4-4B30-B7C7-2264A38B4BFEQ36749168-A8B3F1E6-CEC8-45B4-8E84-B2198A8ED0ADQ37112666-E29D6B2F-8E70-4BAA-9B41-B653C0CB8356Q37334825-8A647FDC-F64B-41BA-B866-61A6F3A73B35Q37368594-78B6DED5-413D-4D2E-80A6-D7A848E8B15DQ37372835-8BC49D09-0B1D-438C-B17C-102B2C171579Q37379320-325E9A0B-7B2A-4CAC-95E5-C6FFCBA24A63Q37710951-EA29DEFA-5920-41B5-B97F-CA2B26ADDAE9Q38380044-28E46BB8-7D74-411F-8BFE-54191341ECE2Q38723094-A0FFCDFD-E20A-4824-B277-2FC6ECE41D3BQ38842352-FE6736F3-51A6-40DC-84FC-D8EA0C10991AQ39757729-C502229B-5DFD-4661-A115-93F8382AC085Q39786673-D94FE0E4-CA71-43E5-97B5-6BDC3C230B2DQ40022357-A13A7B9F-96C6-4873-8BA5-304A0E505010Q40435523-80F5E607-3096-425A-B8DC-D3A1B1B2B811Q40908376-E6D09D34-3B25-4480-B82C-8070FAC8BC6FQ41673629-6BBEDFA9-E06D-4CA2-A1E1-06087F41D2EEQ41942048-495F4C62-0F64-4D04-AE5E-26E29694E4EA
P2860
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
description
1996 nî lūn-bûn
@nan
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
The proto-oncogene product p12 ...... dylinositol-3' kinase pathway.
@ast
The proto-oncogene product p12 ...... dylinositol-3' kinase pathway.
@en
type
label
The proto-oncogene product p12 ...... dylinositol-3' kinase pathway.
@ast
The proto-oncogene product p12 ...... dylinositol-3' kinase pathway.
@en
prefLabel
The proto-oncogene product p12 ...... dylinositol-3' kinase pathway.
@ast
The proto-oncogene product p12 ...... dylinositol-3' kinase pathway.
@en
P2093
P1433
P1476
The proto-oncogene product p12 ...... idylinositol-3' kinase pathway
@en
P2093
J D Griffin
K V Prasad
M A Durstin
P304
P407
P577
1996-02-01T00:00:00Z